What Are the Symptoms of Stage IIIc Gastric Cancer? What Are the Symptoms of Stage IIIc Gastric Cancer? Answer: Hello, in this situation, gastric cancer may have local invasion or retroperitoneal lymph node enlargement. In addition to local symptoms of gastric cancer, there may be severe upper abdominal pain due to enlarged lymph nodes compressing … Read more
Sacituzumab tirumotecan (sac-TMT) is an antibody-drug conjugate targeting trophoblast cell surface antigen 2, which has been shown to significantly extend the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC) who have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy. Methods In this phase III clinical … Read more
Let’s take a look at the recent hot topic of ADC drugs, and systematically learn about the review published in CancersAntibody–Drug Conjugates for the Treatment of Breast Cancer. Abstract Currently, besides endocrine therapy and targeted drugs, metastatic breast cancer (BC) commonly uses chemotherapy as a treatment method. However, the lack of tumor specificity and toxicity … Read more
Introduction The American Society of Clinical Oncology (ASCO) annual meeting is the largest and most authoritative clinical oncology conference in the world, with nearly 40,000 experts from over 100 countries participating. The focus is on cancer-related research, showcasing representative basic and clinical studies, and discussing current international advanced treatment methods. This year’s conference featured 234 … Read more
With the recent approvals of Trastuzumab emtansine (T-DM1) and Gemtuzumab ozogamicin in China, the review of Trastuzumab deruxtecan (T-DXd, DS-8201) is progressing steadily, marking the arrival of a “future” where antibody-drug conjugates (ADCs) greatly benefit breast cancer patients in China. ADCs achieve “precision targeting” of tumors and are referred to as “magic bullets,” changing the … Read more
Although the concept of antibody-drug conjugates (ADCs) seems straightforward, developing successful and effective drugs involves numerous challenges. For a successful ADC product, scientists must optimize various parameters, including ADC stability (for instance, the drug payload should not be released before the ADC reaches its target in the body), pharmacokinetics (e.g., the payload should not accumulate … Read more
Estimated reading timeApproximately 9 minutes, total 3273 words. Introduction Last week, we shared a commentary by Professor Zhang Jian and Dr. Jin Yizi from Fudan University Shanghai Cancer Center on the article “The Incidence of Oral Mucositis and Oral Ulcerative Mucosal Toxicities in Cancer Treatment” published in CA Journal. Did you find it insufficient? Starting … Read more
Editor’s Note On May 11, at the 18th Gastric Cancer Academic Conference (CGCC 2024), Professor Ying Jie’Er from Zhejiang Provincial Cancer Hospital delivered an academic report titled “Treatment of Elderly Patients with Advanced Gastric Cancer”. The content is organized as follows for readers. 1. Epidemiology and Prognosis of Elderly Patients with Advanced Gastric Cancer According … Read more
Follow below to not miss cancer knowledge~ 1 Three Major Therapies for Lung Cancer Have Shortcomings, Urgent Need for Innovative Drugs In recent years, significant progress has been made in the treatment of advanced non-small cell lung cancer, with a growing variety of therapeutic drugs leading to a triad of targeted, immunotherapy, and chemotherapy. Targeted … Read more
Intrahepatic cholangiocarcinoma (ICC) accounts for approximately 10% to 15% of primary liver cancers, and its incidence has been on the rise globally in recent years. The causes and risk factors for ICC are complex, with established risk factors including age, intrahepatic bile duct stones, liver fluke disease, bile duct adenoma, bile duct papillomatosis, bile duct … Read more